• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

ASCO: Novel Drug Safe, Promising in ALL


An investigational immunotherapy was well tolerated and active in patients with acute lymphoblastic leukemia (ALL), a researcher said here.

In a small phase II study, the bi-specific antibody blinatumomab had an "exceptionally high response rate," said Max Topp, MD, of University Hospitals of Wuerzburg in Wuerzburg, Germany.

Over all doses, 72% of the study's 36 patients had a complete response or a hematological complete response within two cycles of treatment, Topp reported at the annual meeting of the American Society of Clinical Oncology. The proportion was slightly higher — 74% -- among the 23 patients who had the safest dose from the start.

Read the full story: http://hcp.lv/JLNsld

Source: MedPage Today

Related Videos
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Sarah Bajorek, PhD, BCACP, MBA.
Pat Van Burkleo
Video 11 - "Social Burden and Goals of Therapy for Patients with Bronchiectasis"
Video 7 - "Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words"
dr monica li
dr lawrence eichenfield
Dr Kevin Mallow, PharmD, BCPS, BC-ADM, CDCES
Video 14 - "Achieving Equitable Representation in Clinical Studies"
Related Content
© 2024 MJH Life Sciences
All rights reserved.